KPTI241220P7500
- 0.00
- 0.000.00%
Karyopharm Therapeutics Newsroom
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Express News | Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
Press Release: Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Cautious Hold Rating on Karyopharm Therapeutics Amid Incremental Revenue Growth and Pending Clinical Trial Outcomes
Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $5
Express News | Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $5
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3
Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5
Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript Summary
H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $7
Karyopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy Rating
Karyopharm Therapeutics | 10-Q: Q3 2024 Earnings Report
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
Karyopharm Therapeutics: Q3 Earnings Snapshot
Karyopharm Expects 2024 Sales Of $145M-$155M Versus Prior Guidance Of $145M-$160M And Consensus Of $152.352M
Karyopharm Therapeutics GAAP EPS of -$0.26 Beats by $0.03, Revenue of $38.78M Beats by $0.86M
Express News | Karyopharm Therapeutics Inc Q3 Shr View $-0.26, Rev View $37.8 Mln -- LSEG IBES Data
Express News | Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress